Human neutralizing antibodies elicited by SARS-CoV-2 infection
Ju，Bin1,2; Zhang，Qi3; Ge，Jiwan4; Wang，Ruoke3; Sun，Jing5; Ge，Xiangyang1; Yu，Jiazhen1; Shan，Sisi3; Zhou，Bing1; Song，Shuo1; Tang，Xian1; Yu，Jinfang4; Lan，Jun4; Yuan，Jing6; Wang，Haiyan1; Zhao，Juanjuan1,2; Zhang，Shuye7; Wang，Youchun8; Shi，Xuanling3; Liu，Lei1,2; Zhao，Jincun5; Wang，Xinquan4; Zhang，Zheng1,2; Zhang，Linqi3
The emerging coronavirus SARS-CoV-2 pandemic presents a global health emergency in urgent need of interventions. SARS-CoV-2 entry into the target cells depends on binding between the receptor-binding domain (RBD) of the viral Spike protein and the ACE2 cell receptor. Here, we report the isolation and characterization of 206 RBD-specific monoclonal antibodies derived from single B cells of eight SARS-CoV-2 infected individuals. We identified antibodies with potent anti-SARS-CoV-2 neutralization activity that correlates with their competitive capacity with ACE2 for RBD binding. Surprisingly, neither the anti-SARS-CoV-2 antibodies nor the infected plasma cross-reacted with SARS-CoV or MERS-CoV RBDs, although substantial plasma cross-reactivity to their trimeric Spike proteins was found. Crystal structure analysis of RBD-bound antibody revealed steric hindrance that inhibits viral engagement with ACE2 and thereby blocks viral entry. These findings suggest that anti-RBD antibodies are viral species-specific inhibitors. The antibodies identified here may be candidates for the development of SARS-CoV-2 clinical interventions.
NI Journal Papers ; NI论文 ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers ; ESI Highly Cited Papers
Science and Technology Innovation Committee of Shenzhen Municipality ; Tsinghua University Initiative Scientific Research Program ; National Beijing Municipal Science and Technology Commission[171100000517-001][171100000517-003] ; National Key Plan for Scientific Research and Development of China[2016YFD0500307]
|WOS Research Area|
Science & Technology - Other Topics
|WOS Accession No|
|ESI Research Field|
BIOLOGY & BIOCHEMISTRY;CLINICAL MEDICINE;MULTIDISCIPLINARY;PLANT & ANIMAL SCIENCE;ENVIRONMENT/ECOLOGY;SOCIAL SCIENCES, GENERAL;MICROBIOLOGY;ECONOMICS BUSINESS;IMMUNOLOGY;MATERIALS SCIENCE;COMPUTER SCIENCE;SPACE SCIENCE;MOLECULAR BIOLOGY & GENETICS;CHEMISTRY;NEUROSCIENCE & BEHAVIOR;PHYSICS;GEOSCIENCES;ENGINEERING
Cited Times [WOS]:943
|Document Type||Journal Article|
|Department||School of Medicine|
1.Institute for Hepatology,National Clinical Research Center for Infectious Disease,Shenzhen Third People’s Hospital,Shenzhen,518112,China
2.The Second Affiliated Hospital,School of Medicine,Southern University of Science and Technology,Shenzhen,518055,China
3.Center for Global Health and Infectious Diseases,Comprehensive AIDS Research Center,and Beijing Advanced Innovation Center for Structural Biology,School of Medicine,Tsinghua University,Beijing,100084,China
4.The Ministry of Education Key Laboratory of Protein Science,Beijing Advanced Innovation Center for Structural Biology,Beijing Frontier Research Center for Biological Structure,Collaborative Innovation Center for Biotherapy,School of Life Sciences,Tsinghua University,Beijing,100084,China
5.State Key Laboratory of Respiratory Disease,National Clinical Research Center for Respiratory Disease,Guangzhou Institute of Respiratory Health,the First Affiliated Hospital of Guangzhou Medical University,Guangzhou,510182,China
6.Department for Infectious Diseases,Shenzhen Third People’s Hospital,Shenzhen,518112,China
7.Shanghai Public Health Clinical Center and Institute of Biomedical Sciences,Fudan University,Shanghai,201508,China
8.Division of HIV/AIDS and Sex-Transmitted Virus Vaccines,National Institutes for Food and Drug Control,Beijing,China
|First Author Affilication||School of Medicine; The Third People's Hospital of Shenzhen|
|Corresponding Author Affilication||School of Medicine; The Third People's Hospital of Shenzhen|
Ju，Bin,Zhang，Qi,Ge，Jiwan,et al. Human neutralizing antibodies elicited by SARS-CoV-2 infection[J]. NATURE,2020,584(7819):115-+.
Ju，Bin.,Zhang，Qi.,Ge，Jiwan.,Wang，Ruoke.,Sun，Jing.,...&Zhang，Linqi.(2020).Human neutralizing antibodies elicited by SARS-CoV-2 infection.NATURE,584(7819),115-+.
Ju，Bin,et al."Human neutralizing antibodies elicited by SARS-CoV-2 infection".NATURE 584.7819(2020):115-+.
|Files in This Item:||There are no files associated with this item.|
|Recommend this item|
|Export to Endnote|
|Export to Excel|
|Export to Csv|
|Similar articles in Google Scholar|
|Similar articles in Baidu Scholar|
|Similar articles in Bing Scholar|
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.